Review



high binding standard elisa microplates  (Greiner Bio)


Bioz Verified Symbol Greiner Bio is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Greiner Bio high binding standard elisa microplates
    Figure 4. BCP suppresses OXA-induced inflammatory cytokine production and spinal cord oxidative damage. (A) <t>ELISA</t> assay quantification of TNF, IL-1β, IL-10, and IL-6 levels, (B) ex vivo DCF assay, (C) TBARS, and (D) 4-HNE content in the spinal cords of tumor-bearing animals treated with OXA with/without BCP (100 mg/kg, gavage, daily) (n = 6–7/group). OXA treatment started on day 0, BCP (100 mg/kg, gavage, daily) started on day 6, and spinal cord tissues were isolated on protocol day 15 for cytokine and oxidative stress evaluation. In (A), the dashed line denotes the assay sensitivity cut-off. * Different from vehicle/control group, # different from OXA group, and & different from both OXA and control groups, considering the same experimental time point (ANOVA; p < 0.05).
    High Binding Standard Elisa Microplates, supplied by Greiner Bio, used in various techniques. Bioz Stars score: 95/100, based on 156 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/high binding standard elisa microplates/product/Greiner Bio
    Average 95 stars, based on 156 article reviews
    high binding standard elisa microplates - by Bioz Stars, 2026-04
    95/100 stars

    Images

    1) Product Images from "β-Caryophyllene Inhibits Oxaliplatin-Induced Peripheral Neuropathy in Mice: Role of Cannabinoid Type 2 Receptors, Oxidative Stress and Neuroinflammation."

    Article Title: β-Caryophyllene Inhibits Oxaliplatin-Induced Peripheral Neuropathy in Mice: Role of Cannabinoid Type 2 Receptors, Oxidative Stress and Neuroinflammation.

    Journal: Antioxidants (Basel, Switzerland)

    doi: 10.3390/antiox12101893

    Figure 4. BCP suppresses OXA-induced inflammatory cytokine production and spinal cord oxidative damage. (A) ELISA assay quantification of TNF, IL-1β, IL-10, and IL-6 levels, (B) ex vivo DCF assay, (C) TBARS, and (D) 4-HNE content in the spinal cords of tumor-bearing animals treated with OXA with/without BCP (100 mg/kg, gavage, daily) (n = 6–7/group). OXA treatment started on day 0, BCP (100 mg/kg, gavage, daily) started on day 6, and spinal cord tissues were isolated on protocol day 15 for cytokine and oxidative stress evaluation. In (A), the dashed line denotes the assay sensitivity cut-off. * Different from vehicle/control group, # different from OXA group, and & different from both OXA and control groups, considering the same experimental time point (ANOVA; p < 0.05).
    Figure Legend Snippet: Figure 4. BCP suppresses OXA-induced inflammatory cytokine production and spinal cord oxidative damage. (A) ELISA assay quantification of TNF, IL-1β, IL-10, and IL-6 levels, (B) ex vivo DCF assay, (C) TBARS, and (D) 4-HNE content in the spinal cords of tumor-bearing animals treated with OXA with/without BCP (100 mg/kg, gavage, daily) (n = 6–7/group). OXA treatment started on day 0, BCP (100 mg/kg, gavage, daily) started on day 6, and spinal cord tissues were isolated on protocol day 15 for cytokine and oxidative stress evaluation. In (A), the dashed line denotes the assay sensitivity cut-off. * Different from vehicle/control group, # different from OXA group, and & different from both OXA and control groups, considering the same experimental time point (ANOVA; p < 0.05).

    Techniques Used: Enzyme-linked Immunosorbent Assay, Ex Vivo, DCF Assay, Isolation, Control



    Similar Products

    Image Search Results